An Evaluation of The Absolute Bioavailability of TH104
Status:
Active, not recruiting
Trial end date:
2024-04-10
Target enrollment:
Participant gender:
Summary
This is a single-dose, single-center, open-label, randomized, 2-way crossover study (2
treatments, 2 periods and 2 sequences) of a buccal formulation of Nalmefene 16 mg and a 1 mg
intravenous dose of nalmefene injection, with a least 7 days washout period between doses.